265 related articles for article (PubMed ID: 33852961)
1. Liver organoid as a 3D in vitro model for drug validation and toxicity assessment.
Brooks A; Liang X; Zhang Y; Zhao CX; Roberts MS; Wang H; Zhang L; Crawford DHG
Pharmacol Res; 2021 Jul; 169():105608. PubMed ID: 33852961
[TBL] [Abstract][Full Text] [Related]
2. Liver Buds and Liver Organoids: New Tools for Liver Development, Disease and Medical Application.
Zeng F; Zhang Y; Han X; Weng J; Gao Y
Stem Cell Rev Rep; 2019 Dec; 15(6):774-784. PubMed ID: 31863336
[TBL] [Abstract][Full Text] [Related]
3. Organoids are promising tools for species-specific in vitro toxicological studies.
Augustyniak J; Bertero A; Coccini T; Baderna D; Buzanska L; Caloni F
J Appl Toxicol; 2019 Dec; 39(12):1610-1622. PubMed ID: 31168795
[TBL] [Abstract][Full Text] [Related]
4. Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids.
Mun SJ; Ryu JS; Lee MO; Son YS; Oh SJ; Cho HS; Son MY; Kim DS; Kim SJ; Yoo HJ; Lee HJ; Kim J; Jung CR; Chung KS; Son MJ
J Hepatol; 2019 Nov; 71(5):970-985. PubMed ID: 31299272
[TBL] [Abstract][Full Text] [Related]
5. Neural organoids for disease phenotyping, drug screening and developmental biology studies.
Hartley BJ; Brennand KJ
Neurochem Int; 2017 Jun; 106():85-93. PubMed ID: 27744003
[TBL] [Abstract][Full Text] [Related]
6. Organoids: Current Implications and Pharmaceutical Applications in Liver Diseases.
Zhu M; Huang Y; Bian S; Song Q; Zhang J; Zheng W; Cheng C
Curr Mol Pharmacol; 2021 Oct; 14(4):498-508. PubMed ID: 33334301
[TBL] [Abstract][Full Text] [Related]
7. High-Fidelity Drug-Induced Liver Injury Screen Using Human Pluripotent Stem Cell-Derived Organoids.
Shinozawa T; Kimura M; Cai Y; Saiki N; Yoneyama Y; Ouchi R; Koike H; Maezawa M; Zhang RR; Dunn A; Ferguson A; Togo S; Lewis K; Thompson WL; Asai A; Takebe T
Gastroenterology; 2021 Feb; 160(3):831-846.e10. PubMed ID: 33039464
[TBL] [Abstract][Full Text] [Related]
8. SCREENED: A Multistage Model of Thyroid Gland Function for Screening Endocrine-Disrupting Chemicals in a Biologically Sex-Specific Manner.
Moroni L; Barbaro F; Caiment F; Coleman O; Costagliola S; Conza GD; Elviri L; Giselbrecht S; Krause C; Mota C; Nazzari M; Pennington SR; Ringwald A; Sandri M; Thomas S; Waddington J; Toni R
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455722
[TBL] [Abstract][Full Text] [Related]
9. Drug compound screening in single and integrated multi-organoid body-on-a-chip systems.
Skardal A; Aleman J; Forsythe S; Rajan S; Murphy S; Devarasetty M; Pourhabibi Zarandi N; Nzou G; Wicks R; Sadri-Ardekani H; Bishop C; Soker S; Hall A; Shupe T; Atala A
Biofabrication; 2020 Feb; 12(2):025017. PubMed ID: 32101533
[TBL] [Abstract][Full Text] [Related]
10. Organoids of liver diseases: From bench to bedside.
Wu LJ; Chen ZY; Wang Y; Zhao JG; Xie XZ; Chen G
World J Gastroenterol; 2019 Apr; 25(16):1913-1927. PubMed ID: 31086460
[TBL] [Abstract][Full Text] [Related]
11. Developing liver organoids from induced pluripotent stem cells (iPSCs): An alternative source of organoid generation for liver cancer research.
Nguyen R; Da Won Bae S; Qiao L; George J
Cancer Lett; 2021 Jun; 508():13-17. PubMed ID: 33771683
[TBL] [Abstract][Full Text] [Related]
12. Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors.
Cao W; Liu J; Wang L; Li M; Verstegen MMA; Yin Y; Ma B; Chen K; Bolkestein M; Sprengers D; van der Laan LJW; Doukas M; Kwekkeboom J; Smits R; Peppelenbosch MP; Pan Q
Carcinogenesis; 2019 Mar; 40(1):145-154. PubMed ID: 30289434
[TBL] [Abstract][Full Text] [Related]
13. Applications of Bioengineered 3D Tissue and Tumor Organoids in Drug Development and Precision Medicine: Current and Future.
Devarasetty M; Mazzocchi AR; Skardal A
BioDrugs; 2018 Feb; 32(1):53-68. PubMed ID: 29383499
[TBL] [Abstract][Full Text] [Related]
14. Application of organoids in translational research of human diseases with a particular focus on gastrointestinal cancers.
Nguyen R; Bae SDW; Zhou G; Read SA; Ahlenstiel G; George J; Qiao L
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188350. PubMed ID: 32007597
[TBL] [Abstract][Full Text] [Related]
15. Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance.
Liu J; Li P; Wang L; Li M; Ge Z; Noordam L; Lieshout R; Verstegen MMA; Ma B; Su J; Yang Q; Zhang R; Zhou G; Carrascosa LC; Sprengers D; IJzermans JNM; Smits R; Kwekkeboom J; van der Laan LJW; Peppelenbosch MP; Pan Q; Cao W
Cell Mol Gastroenterol Hepatol; 2021; 11(2):407-431. PubMed ID: 32932015
[TBL] [Abstract][Full Text] [Related]
16. Updates on Organoid Model for the Study of Liver Cancer.
El-Khobar KE; Sukowati CHC
Technol Cancer Res Treat; 2023; 22():15330338231154090. PubMed ID: 36788421
[TBL] [Abstract][Full Text] [Related]
17. The science and engineering of stem cell-derived organoids-examples from hepatic, biliary, and pancreatic tissues.
Ogoke O; Maloy M; Parashurama N
Biol Rev Camb Philos Soc; 2021 Feb; 96(1):179-204. PubMed ID: 33002311
[TBL] [Abstract][Full Text] [Related]
18. Pluripotent stem cells for target organ developmental toxicity testing.
Wu X; Chen Y; Kreutz A; Silver B; Tokar EJ
Toxicol Sci; 2024 May; 199(2):163-171. PubMed ID: 38547390
[TBL] [Abstract][Full Text] [Related]
19. A decade of liver organoids: Advances in disease modeling.
Liu Y; Sheng JY; Yang CF; Ding J; Chan YS
Clin Mol Hepatol; 2023 Jul; 29(3):643-669. PubMed ID: 36880210
[TBL] [Abstract][Full Text] [Related]
20. Organoids to model liver disease.
Nuciforo S; Heim MH
JHEP Rep; 2021 Feb; 3(1):100198. PubMed ID: 33241206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
